Capital Group Private Client Services, Inc. Bei Gene, Ltd. Transaction History

Capital Group Private Client Services, Inc.

$10.2 Billion
Q4 2024

A detailed history of Capital Group Private Client Services, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Private Client Services, Inc. holds 159,297 shares of BGNE stock, worth $36.1 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

159,297

Previous 182,899 12.9%

Holding current value

$36.1 Million

Previous $41.1 Million 28.34%

% of portfolio

0.29%

Previous 0.41%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$174.72 - $246.04 $4.12 Million - $5.81 Million	-23,602 Reduced 12.9%	159,297 $29.4 Million
Q3 2024 Nov 13, 2024	SELL	$143.93 - $224.51 $1.43 Million - $2.23 Million	-9,941 Reduced 5.16%	182,899 $41.1 Million
Q2 2024 Aug 13, 2024	SELL	$129.52 - $174.32 $2.07 Million - $2.78 Million	-15,960 Reduced 7.64%	192,840 $27.5 Million
Q1 2024 May 14, 2024	BUY	$141.8 - $181.47 $1.64 Million - $2.1 Million	11,579 Added 5.87%	208,800 $32.7 Million
Q4 2023 Feb 13, 2024	SELL	$158.67 - $201.58 $4.12 Million - $5.23 Million	-25,950 Reduced 11.63%	197,221 $35.6 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $778,837 - $974,812	-4,330 Reduced 1.9%	223,171 $40.1 Million
Q2 2023 Aug 11, 2023	SELL	$178.3 - $266.78 $3.32 Million - $4.97 Million	-18,638 Reduced 7.57%	227,501 $40.6 Million
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $2.53 Million - $3.23 Million	-11,749 Reduced 4.56%	246,139 $53.1 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $648,259 - $1.18 Million	-5,165 Reduced 1.96%	257,888 $56.7 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $354,410 - $543,823	-2,689 Reduced 1.01%	263,053 $35.5 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $1.15 Million - $2.04 Million	-9,455 Reduced 3.44%	265,742 $43 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $17.2 Million - $31.6 Million	117,231 Added 74.21%	275,197 $51.9 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $997,719 - $1.56 Million	-4,014 Reduced 2.48%	157,966 $42.8 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $40.4 Million - $65.3 Million	161,980 New	161,980 $58.8 Million

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

42.4M

Call Options Held

135K

Put Options Held

111K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Group Private Client Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital Group Private Client Services, Inc. with notifications on news.

Account

Capital Group Private Client Services, Inc. Bei Gene, Ltd. Transaction History